title: [Therapy refractory pain of malignant origin].
abstract: In 50 patients with intractable pain due to malignancy an intrathecal application of morphine was performed. The follow-up extended in 28 patients till their death. Overall 46% of the patients had a profit of the therapy for the whole remaining life, 25% at least half of it. The main indication to intrathecal infusion of morphine is in multiloculare and midline pain especially in advanced cancer stage.
authors.affiliation: Neurochirurgische Universitätsklinik, Mainz.
authors.forename: P
authors.initials: P
authors.lastname: Grunert
authors.forename: G
authors.initials: G
authors.lastname: Pendl
authors.forename: E
authors.initials: E
authors.lastname: Oztürk
mesh_terms: D000328:Adult; D000368:Aged; D015360:Analgesia, Epidural / Q000295:instrumentation*; D002408:Catheters, Indwelling; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage* / Q000009:adverse effects; D009369:Neoplasms / Q000503:physiopathology*; D010147:Pain Measurement; D010148:Intractable Pain / Q000188:drug therapy*
chemical_list: D009020:Morphine
vernacular_title: Therpieresistente Schmerzen maligner Genese.